HomeNewsBusinessExplained| Why IndiGo's promoters fell out and how the upcoming EGM can settle the dispute

Explained| Why IndiGo's promoters fell out and how the upcoming EGM can settle the dispute

The eyeball to eyeball confrontation between the airline's promoters Rahul Bhatia and Rakesh Gangwal may finally end if the EGM removes restrictions on the transfer of promoter shares.

December 09, 2021 / 15:08 IST
Story continues below Advertisement
Representative image
Representative image

The spat between Rahul Bhatia and Rakesh Gangwal, promoters of InterGlobe Aviation, the company that operates India's largest domestic airline IndiGo, is on the verge of being resolved.

The airline has called an extraordinary-general meeting on December 30, to amend its Articles of Association and remove restrictions on the transfer of promoter shares.

Story continues below Advertisement

However, unlike in 2019, when Gangwal had called an EGM to amend IndiGo’s Art¬icles of Association, this time around both Gangwal and Bhatia, who collectively hold 74.44 percent of the paid-up equity share capital of InterGlobe, have called for an EGM.

The resolution to amend the company’s Articles of Association is expected to pass smoothly, given that both the promoters have jointly called the shareholder meeting

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show